Live Accenture Plc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow ProtoKinetix, Inc.

Get SEC filing alerts via email and in your feed for ProtoKinetix, Inc.

PKTX

ProtoKinetix, Inc.

About ProtoKinetix, Inc.

ProtoKinetix, Inc. is a biotech research company developing anti-aging glycoproteins (AAGPs) for medical applications. Focused on scientific validation and commercialization, it explores therapies for cell preservation and regenerative medicine. Operating primarily through collaborations, it holds intellectual property, seeks regulatory approval, and aims to bring innovative health solutions to large markets. The company relies on funding, partnerships, and intellectual property protection.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from ProtoKinetix, Inc.

1
1
ProtoKinetix, Inc. ProtoKinetix Reports Increased Net Loss and Operating Expenses for Nine Months Ending September 30, 2025

Via official filing (AI summary) | 7 months ago | 0 comments

2
1
ProtoKinetix, Inc. ProtoKinetix Reports Increased Net Loss and Operating Expenses for Six Months Ending June 30, 2025

Via official filing (AI summary) | 10 months ago | 0 comments

3
1
ProtoKinetix, Inc. ProtoKinetix Reports Q1 2025 Financial Results with Increased Net Loss and Asset Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

4
1
ProtoKinetix, Inc. ProtoKinetix Reports Decreased Net Loss and Increased Financial Strain for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

5
1
ProtoKinetix, Inc. ProtoKinetix Reports Net Loss, Decline in Cash and Working Capital, and Doubts Over Going Concern

Via official filing (AI summary) | over 1 year ago | 0 comments